Intratympanic Dexamethasone efficacy in sudden SNHL Versus Oral Deflazacort in Sudden Sensorineural Hearing Loss

Efficacy of Intratympanic Dexamethasone and Oral Deflazacort in Sudden Sensorineural Hearing Loss- A Randomized Single Blind Trial - NIL

Status

Active, not recruiting

Phases

Phase 4

Study type

Interventional

Source

CTRI

Registry ID

CTRI/2025/04/085843

Enrollment

Registered

2025-04-28

Start date

Unknown

Completion date

Unknown

Last updated

2025-05-26

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Health Condition 1: H839- Unspecified disease of inner ear

Interventions

Intervention1: INTRATYMPANIC DEXAMETHASONE (Randomized controlled trial): GROUP-A Patients receiving intratympanic dexamethasone (0.5 ml 0r 2mg/ml - 3 doses, intratympanic route, 21 days)) Interventi

Eligibility

Inclusion criteria

Inclusion criteria: 1. Patients diagnosed with sudden SNHL for the first time (duration less than or equal to 7 days). 2. Patients with age group 18-65 years.

Exclusion criteria

Exclusion criteria:

Design outcomes

Primary

Measure	Time frame
To compare the improvement of hearing by intratympanic dexamethasone versus oral deflazacort in sudden sensorineural hearing loss (SSNHL).Timepoint: 1 week & 3 weeks	—

Secondary

Measure	Time frame
To compare the tolerability & side effects of intratympanic dexamethasone & oral deflazacort in patients under treatment for sudden sensorineural hearing loss. Timepoint: 1 week & 3 weeks	—

Countries

India

Contacts

Public ContactLIPSY

KALINGA INSTITUTE OF MEDICAL SCIENCES, BHUBANESWAR, ODISHA

drmanas.1976@gmail.com9701476440

Outcome results

None listed

Source: CTRI (via WHO ICTRP) · Data processed: Feb 4, 2026